Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Restory: an online, anonymous trauma therapy for adults affected by sexual abuse

Official title: A Randomised Waitlist Controlled Clinical Trial of the Restory Trauma Treatment Program

Run by Karolinska Institutet · NCT07610187 · Data updated 2026-11-12

A free, anonymous online therapy program called Restory tests whether it helps reduce PTSD symptoms in adults who experienced sexual abuse, compared with a waitlist control.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment140 (estimated)
SponsorKarolinska Institutet
Academic / other
Locations1 site (Stockholm)
StatusRecruiting
StartedMay 4, 2026
Main results expectedMay 4, 2027
Study endsNovember 4, 2027
Registry record updatedAugust 7, 2026
Trial IDNCT07610187 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18 or older with a history of sexual violence, a PCL-5 score of at least 30, and stable or no psychotropic medication, who can use Swedish and participate remotely.

Probably not a fit

Individuals with ongoing acute trauma threats, severe psychiatric conditions requiring immediate care, current trauma-focused therapy, benzodiazepine treatment, or no trauma memory may be less likely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Restory is an anonymous internet-based cognitive behavioral therapy program providing prolonged exposure for adults who have experienced sexual abuse. In a pre-registered randomized controlled trial, participants are assigned to either the Restory treatment or a waitlist control to see if PTSD symptom severity (PCL-5) improves more with Restory. The program aims to increase accessibility and reduce barriers to care by offering nationwide, low-threshold treatment that can be used remotely. iCBT has shown promise for PTSD, and Restory seeks to determine its effectiveness specifically for sexual abuse victims in Sweden. The study also notes potential benefits in self-efficacy and engagement through a patient-directed treatment approach.

Why it matters

Potential benefit: If successful, Restory could provide a scalable, accessible option for reducing PTSD symptoms in sexual abuse survivors who face barriers to traditional care.

How similar studies have gone: Previous internet-based PTSD therapies have shown efficacy, though results vary; this trial tests a specific anonymous iCBT prolonged exposure approach for sexual abuse survivors.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18+ years
* exposure to sexual violence where a minimum of 1 month has passed since the incident
* self-reported total PCL-5 of minimum 30
* current stable dose of psychotropic medication (for at least 4 weeks) or medication free
* sufficient Swedish skills
* willingness and availability to participate

Exclusion Criteria:

* Ongoing trauma-related threat (e.g. living with a violent spouse)
* severe psychiatric illness requiring immediate alternative treatment (such as high acute suicide risk or presence of psychotic episode, assessed during screening interview)
* current participation in other trauma-focused CBT or Eye Movement Desensitization and Reprocessing therapy
* current benzodiazepine treatment
* no trauma memory

Where it's running

  • Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet
    Stockholm, Sweden
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.